FDA Approves Arcutis’ Roflumilast Cream 0.15% for the Treatment of AD in Adults and Children Down to Age 6
The U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for roflumilast cream 0.15% (Zoryve, Arcutis), a next-generation topical phosphodiesterase 4 (PDE4) inhibitor, for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients six years of age and older. Lawrence F. Eichenfield, MD, Professor of Dermatology […]